Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K35/76

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/084111COLIPHAGES AND USES THEREOF
WO 06.05.2021
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/EP2020/080600 Applicant INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT Inventor PETIT, Marie-Agnès
The present invention relates to bacteriophages and their use in therapy. More particularly, the present invention relates to novel bacteriophages having a lytic against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
2.WO/2021/084282VIRUSES WITH MODIFIED CAPSID PROTEINS
WO 06.05.2021
Int.Class C12N 15/861
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
861Adenoviral vectors
Appl.No PCT/GB2020/052774 Applicant SPYBIOTECH LIMITED Inventor DICKS, Matthew
This invention relates to preparations comprising adenoviral vectors with modified capsid proteins. These modified capsid proteins enable customisable decoration of the adenoviral vector to be performed, enabling diverse applications from personalised cancer vaccines to targeted gene therapy vectors, and mixtures of the same. In particular, the adenoviral vectors with modified capsid proteins may be modified in the hexon and/or pIX capsid proteins. The invention makes use of peptide pairs to provide a "primed" adenovirus which is ready for decoration.
3.20210128653REPLICATION-ENHANCED ONCOLYTIC ADENOVIRUSES
US 06.05.2021
Int.Class A61K 35/761
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
761Adenovirus
Appl.No 17091549 Applicant MEMGEN, Inc. Inventor Mark J. CANTWELL

Disclosed are replication-enhanced oncolytic adenoviruses. These oncolytic adenoviruses have tumor-specific replication capable of enhanced tumor oncolysis and enhanced therapeutic transgene expression. Also disclosed are methods comprising administering a replication-enhanced oncolytic adenovirus for patients suffering from a cancer.

4.20210128652AAV TRANSFER CASSETTE
US 06.05.2021
Int.Class A61K 35/761
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
761Adenovirus
Appl.No 17072637 Applicant StrideBio, Inc. Inventor David Dismuke

Described herein are AAV transfer cassettes and plasmids used in the production of recombinant adeno-associated viral (rAAV) vectors. The disclosed cassettes and plasmids comprise one or more transgenes having therapeutic efficacy in the amelioration, treatment and/or prevention of one or more diseases or disorders, such as Niemann-Pick Disease, type C1 (NPC1).

5.WO/2021/087019ONCOLYTIC VIROTHERAPY WITH INDUCED ANTI-TUMOR IMMUNITY
WO 06.05.2021
Int.Class A61K 35/763
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
763Herpes virus
Appl.No PCT/US2020/057820 Applicant UNIVERSITY OF HOUSTON SYSTEM Inventor ZHANG, Shaun, Xiaoliu
Provided are improved oncolytic viruses with increased bystander cell killing and induced anti-tumor immunity. The oncolytic viruses include an oncolytic herpes virus backbone genetically modified to encode a tumor cell binding component and an immunoglobulin (Ig) binding component.
6.WO/2021/087394TYPE I-B CRISPR-ASSOCIATED TRANSPOSASE SYSTEMS
WO 06.05.2021
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
Appl.No PCT/US2020/058405 Applicant THE BROAD INSTITUTE, INC. Inventor SAITO, Makoto
Systems and methods for targeted gene modification, targeted insertion, perturbation of gene transcripts, and nucleic acid editing. Novel nucleic acid targeting systems comprise components of CRISPR systems and transposable elements.
7.20210121511VIRUS-LIKE PARTICLE COMPOSITIONS AND METHODS OF USING SAME
US 29.04.2021
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No 17058565 Applicant Henry C. Lin Inventor Henry C. Lin

A pharmaceutical composition includes a preparation of virus-like particles (VLPs) obtained from the gastrointestinal tract of a subject and a pharmaceutically-acceptable carrier. The VLPs can include bacteriophages, eukaryotic viruses, or gene transfer agents. A VLP composition may be administered to a subject having, or at risk of having dysbiosis, in an amount effective to amelio-rate at least one symptom or clinical sign of dysbiosis. A VLP composition also may be administered to a subject in preparation for administering a source of bacteria, to improve the receptivity of subject's gut to source of bacteria.

8.WO/2021/079435BACTERIOPHAGE COMPOSITION
WO 29.04.2021
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/JP2019/041541 Applicant MEIJI SEIKA PHARMA CO., LTD. Inventor IWANO Hidetomo
This composition is for lysing Staphylococcus aureus or treating or preventing diseases caused by Staphylococcus aureus, and contains, as active ingredients, at least one bacteriophage selected from the group consisting of the bacteriophage specified by Deposit No. NITE BP-693 and the bacteriophage specified by Deposit No. NITE BP-694, and an endolysin, which is at least one protein selected from the group consisting of (a) a protein having the amino acid sequence described in SEQ ID NO: 1, (b) proteins having amino acid sequences having at least 80% identity with the amino acid sequence described in SEQ ID NO: 1, and (c) proteins having amino acid sequences obtained by providing at least one amino acid substitution, deletion, addition, and/or insertion to the amino acid sequence described in SEQ ID NO: 1.
9.281299METHOD FOR PRODUCING AN ANTITUMORAL ARENAVIRUS AS WELL AS ARENAVIRUS MUTANTS
IL 29.04.2021
Int.Class A61K 35/768
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
768Oncolytic viruses not provided for in groups A61K35/761-A61K35/76697
Appl.No 281299 Applicant ABALOS THERAPEUTICS GMBH Inventor
10.WO/2021/079536BACTERIOPHAGE COMPOSITION
WO 29.04.2021
Int.Class A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
Appl.No PCT/JP2020/004908 Applicant MEIJI SEIKA PHARMA CO., LTD. Inventor IWANO Hidetomo
This composition for lysis of Staphylococcus aureus or this composition for prevention or therapy of diseases caused by Staphylococcus aureus contains as active ingredients: at least one bacteriophage selected from the group consisting of the bacteriophage identified by Accession No. NITE BP-693 and the bacteriophage identified by Accession No. NITE BP-694; and an endolysin that is at least one protein selected from the group consisting of (a) a protein having the amino acid sequence of SEQ ID NO: 1; (b) proteins having an amino acid sequence having 80% or more identity to the amino acid sequence of SEQ ID NO: 1; and (c) proteins having an amino acid sequence obtained by providing one or more amino acid substitutions, deletions, additions, and/or insertions to the amino acid sequence of SEQ ID NO: 1.